Published in PLoS One on October 26, 2011
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol (2013) 1.04
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition. Oncoimmunology (2014) 0.78
Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma. Immunotherapy (2012) 0.76
Opening a niche for therapy: local lymphodepletion helps the immune system to fight melanoma. J Invest Dermatol (2014) 0.75
Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep (2016) 0.75
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 10.22
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 6.80
Memory CD8 T-cell differentiation during viral infection. J Virol (2004) 6.75
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
T-cell exhaustion: characteristics, causes and conversion. Immunology (2010) 2.24
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res (2010) 1.91
Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol (2000) 1.87
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun (2002) 1.80
Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol (2007) 1.78
Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol (2004) 1.59
Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol (2006) 1.51
CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol (2007) 1.50
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer (1997) 1.28
Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol (1994) 1.27
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol (2009) 1.26
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol (2007) 1.14
Differences in the degree of depletion, rate of recovery, and the preferential elimination of naive CD4+ T cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J Immunol (1995) 1.11
Comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells". J Immunol (2006) 1.08
Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res (2010) 1.08
Effector and memory CD8+ T cells can be generated in response to alloantigen independently of CD4+ T cell help. J Immunol (2006) 1.07
Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol (1995) 1.07
CD8 T cell memory development: CD4 T cell help is appreciated. Immunol Res (2007) 1.06
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J Immunol (2007) 1.03
Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer (2010) 0.95
Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res (2008) 0.92
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol (2009) 0.92
Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol (2011) 0.87
Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol (2007) 0.86
CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat (2010) 0.82
Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen. J Immunol (2010) 0.81
Depleting anti-CD4 monoclonal antibody (GK1.5) treatment: influence on regulatory CD4+CD25+Foxp3+ T cells in mice. Transplantation (2008) 0.80
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27
Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24
Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol (2006) 1.21
Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol (2009) 1.18
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene (2003) 1.16
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res (2003) 1.07
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 1.04
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J Immunol (2008) 1.02
IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol (2011) 0.99
Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int (2010) 0.98
p38 MAP kinase regulation of oligodendrocyte differentiation with CREB as a potential target. Neurochem Res (2007) 0.97
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res (2008) 0.92
Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition. J Clin Invest (2008) 0.92
Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol (2003) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther (2002) 0.87
Clonal immortalized human glial cell lines support varying levels of JC virus infection due to differences in cellular gene expression. J Neuroimmune Pharmacol (2013) 0.86
Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung (2013) 0.86
Synthesis and characterization of novel reversible photoswitchable fluorescent polymeric nanoparticles via one-step miniemulsion polymerization. J Phys Chem B (2011) 0.86
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) (2013) 0.84
Three-dimensional culture of human uterine smooth muscle myocytes on a resorbable scaffolding. Tissue Eng (2003) 0.80
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
Effects of thyroxine on cardiac function and lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Chin Med J (Engl) (2003) 0.78
The signaling mechanisms of long distance intercellular calcium waves (far waves) in cultured human uterine myocytes. J Muscle Res Cell Motil (2002) 0.76
A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy. Chem Commun (Camb) (2015) 0.75
Design and synthesis of FRET-mediated multicolor and photoswitchable fluorescent polymer nanoparticles with tunable emission properties. J Phys Chem B (2012) 0.75
Ratiometric detection and imaging of endogenous hypochlorite in live cells and in vivo achieved by using an aggregation induced emission (AIE)-based nanoprobe. Chem Commun (Camb) (2016) 0.75